177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).

Shahneen Sandhu; Shalini Subramaniam; Hayley Thomas; Thean Hsiang Tan; Jeffrey C Goh; Nattakorn Dhiantravan; Andrew James Weickhardt; Anthony M Joshua; Ian David Kirkwood; Sze Ting Lee; Craig Gedye; Andrew Nguyen; David A Pattison; Ramin Alipour; Roslyn J Francis; Michael S Hofman; Andrew James Martin; Martin R Stockler; Ian D Davis; Louise Emmett

Journal article

177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).

Shahneen Sandhu, Shalini Subramaniam, Hayley Thomas, Thean Hsiang Tan, Jeffrey C Goh, Nattakorn Dhiantravan, Andrew James Weickhardt, Anthony M Joshua, Ian David Kirkwood, Sze Ting Lee, Craig Gedye, Andrew Nguyen, David A Pattison, Ramin Alipour, Roslyn J Francis, Michael S Hofman, Andrew James Martin, Martin R Stockler, Ian D Davis, Louise Emmett

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2025

DOI: 10.1200/jco.2025.43.16_suppl.5016

Abstract

5016 Background: LuPSMA improves progression-free survival (PFS) and overall survival (OS) in patients with mCRPC. Immune checkpoint inhibitors (ICI) have limited single-agent activity in mCRPC. Radiation may enhance ICI activity by inducing immunogenic tumor cell death and altering the tumor microenvironment. We evaluated the activity and safety of ipi plus nivo plus LuPSMA in mCRPC. Methods: Eligibility: prior androgen receptor pathway inhibitor therapy, PSMA-positive disease, normal organ function, no contraindications to ICIs, <= 1 line of chemotherapy. Randomized (1:2) to LuPSMA alone (7.4 GBq every 6 weeks, up to 6 d..

View full abstract